SELECTION FOR TRANSARTERIAL CHEMOEMBOLIZATION TREATMENT (STATE) Score
Selection For TranArterial chemoembolization TrEatment (STATE) Score as a prognostic tool has been validated in an independent and external validation cohort. It is independent from the performance status, the TACE-type
used, the etiology of the underlying
liver disease.
STATE-score : Serum albumin (g/L) – 12 (if up-to-7 out) – 12 (if CRP levels >1 m/dl)
A STATE score of < 18 has been reported with higher rate of serious side effects associated with first TACE as well as higher short term mortality.¹
| Parameters | Points |
|---|---|
| Albumin (g/L) | Value = Points |
| CRP > 1 mg/dl | - 12 |
| Tumor Size and Number (up-to-seven criteria) > 7 (out) | - 12 |
| Total | < 18 = Increased risk of mortality after first TACE ≥ 18 = Low risk of mortality after first TACE |
- Hucke F, Pinter M, Graziadei I, Bota S, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-Radosavljevic M, Sieghart W. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. Journal of hepatology. 2014 Dec 1;61(6):1287-96.
- Karademir S. Staging of hepatocellular carcinoma. Hepatoma Res. 2018;4:58.
- Kinoshita, Akiyoshi et al. “Staging systems for hepatocellular carcinoma: Current status and future perspectives.” World journal of hepatology vol. 7,3 (2015): 406-24. doi:10.4254/wjh.v7.i3.406